scholarly journals Detecting recurrent head and neck cancer using electronic nose technology: A feasibility study

Head & Neck ◽  
2019 ◽  
Vol 41 (9) ◽  
pp. 2983-2990 ◽  
Author(s):  
Rens M. G. E. Goor ◽  
Joey C. A. Hardy ◽  
Michel R. A. Hooren ◽  
Bernd Kremer ◽  
Kenneth W. Kross
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Feasibility Study ◽  
Neck Cancer ◽  
Electronic Nose ◽  
Electronic Nose Technology ◽  
Recurrent Head

Salvage Stereotactic Reirradiation With or Without Cetuximab for Locally Recurrent Head-and-Neck Cancer: A Feasibility Study

2012 ◽  
Vol 84 (1) ◽  
pp. 203-209 ◽  
Author(s):  
Bénédicte Comet ◽  
Andrew Kramar ◽  
Mathieu Faivre-Pierret ◽  
Sylvain Dewas ◽  
Bernard Coche-Dequeant ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Feasibility Study ◽  
Neck Cancer ◽  
Locally Recurrent ◽  
Recurrent Head

scholarly journals Automated Non-Coplanar VMAT for Dose Escalation in Recurrent Head and Neck Cancer Patients

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1910
Author(s):  
Kaley Woods ◽  
Robert K. Chin ◽  
Kiri A. Cook ◽  
Ke Sheng ◽  
Amar U. Kishan ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Dose Escalation ◽  
Volumetric Modulated Arc Therapy ◽  
Normal Tissue Complication Probability ◽  
Tumor Control ◽  
Tumor Control Probability ◽  
Increased Risk ◽  
Recurrent Head

This study evaluates the potential for tumor dose escalation in recurrent head and neck cancer (rHNC) patients with automated non-coplanar volumetric modulated arc therapy (VMAT) stereotactic body radiation therapy (SBRT) planning (HyperArc). Twenty rHNC patients are planned with conventional VMAT SBRT to 40 Gy while minimizing organ-at-risk (OAR) doses. They are then re-planned with the HyperArc technique to match these minimal OAR doses while escalating the target dose as high as possible. Then, we compare the dosimetry, tumor control probability (TCP), and normal tissue complication probability (NTCP) for the two plan types. Our results show that the HyperArc technique significantly increases the mean planning target volume (PTV) and gross tumor volume (GTV) doses by 10.8 ± 4.4 Gy (25%) and 11.5 ± 5.1 Gy (26%) on average, respectively. There are no clinically significant differences in OAR doses, with maximum dose differences of <2 Gy on average. The average TCP is 23% (± 21%) higher for HyperArc than conventional plans, with no significant differences in NTCP for the brainstem, cord, mandible, or larynx. HyperArc can achieve significant tumor dose escalation while maintaining minimal OAR doses in the head and neck—potentially enabling improved local control for rHNC SBRT patients without increased risk of treatment-related toxicities.

PO-1026 Re-irradiation with concurrent Nivolumab in locally recurrent Head and Neck Cancer

2021 ◽  
Vol 161 ◽  
pp. S855
Author(s):  
J. von der Grün ◽  
A. Altay-Langguth ◽  
P. Balermpas ◽  
C. Brandts ◽  
S. Balster ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Recurrent ◽  
Recurrent Head

Arterial spin labelling and diffusion-weighted magnetic resonance imaging in differentiation of recurrent head and neck cancer from post-radiation changes

2018 ◽  
Vol 132 (10) ◽  
pp. 923-928 ◽  
Author(s):  
A A K Abdel Razek
Keyword(s):  
Blood Flow ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Arterial Spin Labelling ◽  
Tumour Blood Flow ◽  
Apparent Diffusion ◽  
Post Radiation ◽  
Recurrent Head ◽  
Tumour Blood

AbstractObjectiveTo assess arterial spin labelling and diffusion-weighted imaging in the differentiation of recurrent head and neck cancer from post-radiation changes.MethodsA retrospective study was conducted of 47 patients with head and neck cancer, treated with radiotherapy, who underwent magnetic resonance arterial spin labelling and diffusion-weighted magnetic resonance imaging. Tumour blood flow and apparent diffusion co-efficient of the lesion were calculated.ResultsThere was significant difference (p= 0.001) in tumour blood flow between patients with recurrent head and neck cancer (n= 31) (47.37 ± 16.3 ml/100 g/minute) and those with post-radiation changes (n= 16) (18.80 ± 2.9 ml/100 g/minute). The thresholds of tumour blood flow and apparent diffusion co-efficient used for differentiating recurrence from post-radiation changes were more than 24.0 ml/100 g/minute and 1.21 × 10−3mm2/second or less, with area under the curve values of 0.94 and 0.90, and accuracy rates of 88.2 per cent and 88.2 per cent, respectively. The combined tumour blood flow and apparent diffusion co-efficient values used for differentiating recurrence from post-radiation changes had an area under the curve of 0.96 and an accuracy of 90.2 per cent.ConclusionCombined tumour blood flow and apparent diffusion co-efficient can differentiate recurrence from post-radiation changes.

Sign in / Sign up

Export Citation Format

Share Document